Akebia Therapeutics Stock Earnings Reports

Akebia reported strong early-2026 commercial momentum for Vafseo (vadadustat) with Q1 net product revenue of $15.8 million — the highest quarter-to-date — and nearly 7,500 patients on therapy at quarter end (a ~60% increase vs. Q4 2025). Management attributes the acceleration to dialysis organizations shifting to observed (3x weekly) dosing protocols, broader prescriber adoption (≈1,025 prescribers, ~28% QoQ increase) and improved first-refill adherence (~86% under observed dosing). Key upcoming clinical readouts include VOCAL (top-line by year-end 2026) and VOICE (early 2027) — both 3x weekly dialysis studies — which could further support Vafseo versus ESAs. The company is also advancing a kidney-focused R&D portfolio: a Phase II study of praliciguat in FSGS (up to ~60 patients; 24‑week UPCR primary endpoint), a planned Phase II open-label basket trial for AKB‑097 (Abribafisp) in IgA nephropathy, lupus nephritis and C3 glomerulopathy (initiation H2 2026; initial data in 2027), and a Phase I SAD/MAD study of AKB‑9090 for prevention of cardiac surgery–associated AKI (top-line early 2027). Financially, total revenues were $53.5M in Q1 2026 (down vs. $57.3M a year ago) driven by lower Auryxia sales due to generic competition, partially offset by higher Vafseo revenue. Cost of goods, R&D and SG&A increased YoY, producing a Q1 net loss of $9.1M vs. net income a year earlier. Cash & equivalents totaled $162.6M at March 31, 2026; management expects existing resources plus cash from operations to fund the current plan for at least two years. Key investor takeaways: accelerating real-world adoption of Vafseo driven by observed dosing protocols, important upcoming VOCAL/VOICE readouts, a diversified kidney disease pipeline with multiple near-term milestones, and a multi-quarter cash runway despite short-term revenue pressure from Auryxia generic competition.